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Abstract
Background: Crocin, one of the main constituents of saffron extract, has numerous biological effects such as
anti-cancer effects. Multidrug resistance-associated proteins 1 and 2 (MRP1 and MRP2) are important elements in
the failure of cancer chemotherapy. In this study we aimed to evaluate the effects of crocin on MRP1 and MRP2
expression and function in human ovarian cancer cell line A2780 and its cisplatin-resistant derivative A2780/RCIS cells.
Methods: The cytotoxicity of crocin was assessed by the MTT assay. The effects of crocin on the MRP1 and MRP2
mRNA expression and function were assessed by real-time RT-PCR and MTT assays, respectively.
Results: Our study indicated that crocin reduced cell proliferation in a dose-dependent manner in which the
reduction in proliferation rate was more noticeable in the A2780 cell line compared to A2780/RCIS. Crocin
reduced MRP1 and MRP2 gene expression at the mRNA level in A2780/RCIS cells. It increased doxorubicin
cytotoxicity on the resistant A2780/RCIS cells in comparison with the drug-sensitive A2780 cells.
Conclusion: Totally, these results indicated that crocin could suppress drug resistance via down regulation
of MRP transporters in the human ovarian cancer resistant cell line.
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Background
Cancer is a leading cause of death in the world that
broadly affects more and less economically developed
countries [1]. Using different chemotherapy regimens
is a common method in cancer treatment, but there is
some limitation on the effectiveness of chemotherapy
that leads to poor therapeutic results [2]. One of the
most important reasons of treatment failure during
chemotherapy is the multidrug resistance (MDR)
phenomenon. The MDR tumors are resistant to che-
motherapeutic agents which are structurally and func-
tionally different from the initial anticancer drug.
Typical MDR occurs through overexpression of the
membrane efflux proteins that pump anticancer drugs out
of the cells [3]. These pharmaceutical transporter proteins
belong to the ATP-binding cassette transporters family
(ABC family) [4, 5]. One important class of the ABC fam-
ily is the human multidrug resistance-associated protein
(MRP) family which contains seven members. Several
members of the MRP family especially MRP1 and MRP2
are involved in the detoxification and protection of the
host against xenobiotic materials. They are also assumed
to cause drug resistance through their ability in transport-
ing a wide range of anticancer drugs out of the cells and
their presence in many different types of tumors [6].
In the last decades, different research explored new
botanical candidates with potential anti-cancer effects
that has opened a window to developing safer and more
effective anti-cancer therapies [7, 8]. Crocus sativus is a
plant of the Iridaceae family. Stigmas of Crocus sativus
flowers (saffron) contain various chemical substances
[9]. Crocin is a major glycosylated carotenoid found in
saffron [10] that has various pharmacological effects
like protecting the myocardial cell against hypoxia
damage [11], antioxidant [12, 13], anti-atherosclerosis
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[14, 15], antidepressant [16] and anti-inflammatory ef-
fects [17, 18]. In addition, different studies have shown
anticancer activities of crocin against human leukemia,
breast, colorectal, and bladder cancer cell lines [19–23].
Based on these facts, it is expected that crocin could
potentially be used clinically for the prevention and
treatment of cancer in the near future.
It has shown that crocin inhibits Lipopolysaccharides
(LPS)-induced nitric oxide (NO) release from brain
microglial cells and reduces the LPS-stimulated pro-
ductions of tumor necrosis factor-alpha, interleukin-1
beta, and intracellular reactive oxygen species, which ef-
fectively cause decreased NF-kappa B activation [17, 24].
On the other hand, it has been previously showed that
sulindac, the nonsteroidal anti-inflammatory drug, gen-
erates oxidative stress via induction of reactive oxygen
species (ROS) production, which finally leads to the
higher expression of MRP1 and MRP3 in human colo-
rectal cancer cell lines [25]. These evidences suggest
that crocin might affect the protein expression of MDR
proteins. In the present study, we aimed to evaluate the
effects of crocin on the expression and function of
MRP1 and MRP2 in the human ovarian carcinoma cell
lines A2780 and its cisplatin-resistant derivative A2780/
RCIS cells (MRP2-overexpressing cell line).
Methods
Materials
Fetal bovine serum (FBS) and RPMI 1640 with L-glutamine
were purchased from Gibco (USA) and Biosera (UK),
respectively. MTT, DMSO, trypan blue, doxorubicin
and penicillin G/streptomycin were obtained from
Sigma-Aldrich (Germany). Crocin was generously pro-
vided by Dr. Seyed Ahmad Mohajeri (Pharmaceutical
Research Center, Mashhad University of Medical Sciences,
Iran). RNA tripure isolation kit was obtained from Roche
Applied Science, Germany and Real-time EXPRESS
One-Step SYBR GreenER™ Kit was purchased from
Invitrogen, USA. The MRP-overexpressing, cisplatin-
resistant ovarian cancer cell line, A2780/RCIS and its
parental cisplatin sensitive cell line A2780 were gener-
ously provided by Professor Herman Lage (Molecular
Pathology Department, Charite Campus Mitte, Berlin,
Germany).
Preparation of the crocin solution
Total crocin was extracted and crystallized from saf-
fron stigmas and its purity was tested with HPLC and
was more than 96 % [26]. Crocin was dissolved in
DMSO (dimethyl sulfoxide) and PBS to a final concen-
tration of 1024 mM and stored at −20 °C. The drug
was freshly diluted to its final concentration (10, 20,
40, 60, 80 and 100 μM) in culture medium prior to the
start of each experiment.
Cell culture and treatment
Cells were cultured in RPMI-1640 contained FBS
10 % (v/v), penicillin (100 U/mL), and streptomycin
(100 μg/mL) at 37 °C in humidified air containing
CO2 5 %. For MTT and real-time PCR studies, ovar-
ian cancer cells were incubated for 4–72 h with cro-
cin (0–100 μM). For MRP activity analysis, all cell
lines were co-treated with different concentrations of
crocin (0–100 μM) and doxorubicin (0–500 nM) for
4–72 h. This study was obtained the approval of the
Research Ethics Committee of Mashhad University of
Medical Sciences (code No: IR.MUMS.REC.1390.301).
MTT cytotoxicity assay
Drug sensitivity of the A2780 cell line and drug-resistant
cell line A2780/RCIS were confirmed by MTT assay.
Cells were seeded at an initial density of 104 cells/well in
96-well plates. The plates were incubated at 37 °C in a
5 % CO2-supplemented atmosphere for 24 h. Subconflu-
ent cells were treated with different concentrations of
crocin and doxorubicin in a final volume of 100 μl of
standard growth medium in each well. The control wells
had DMSO in the growth medium at equal volumes to
those used for the test compounds. Cell viability was mea-
sured after 4–72 h, using 3-(4, 5-dimethylthiazol-2-yl)-2,
5-diphenyl tetrazolium bromide (MTT). The reduced
MTT dye was solubilized with DMSO (100 μl/well) and
absorbance was determined on an ELISA plate reader
(BioTek, Bad Friedrichshall, Germany) with a test wave-
length of 550 nm and a reference wavelength of
630 nm. Each experiment was performed in triplicate
and was repeated at least three times. The percentage
of cell proliferation was calculated using the ratio of
ODtest/ODcontrol.
Real-Time RT-PCR
Total cellular RNA was extracted using tripure isolation
reagent. The total amount of RNA was measured using
a NanoDrop 1000 spectrophotometer (Thermo Fisher
Scientific, Wilmington, DE) and the acceptable purity
was in the range of 1.8-2.2 for the A260/A230 and
A260/A280 ratios. Real-time RT-PCR was performed to
measure the expression levels of MRP1 and MRP2 in
ovarian cancer cell lines using the EXPRESS One-Step
SYBR GreenER™ Kit and real-time cycler Mx3000P™
Stratagen (Stratagen, USA). The primers had the fol-
lowing sequences: MRP1: 5´-GTGTTTCTGGTCAGCC
CAACT-3´ (forward) and 5´-TTGGATCTCAGGATGG
CAGG-3´ (reverse); MRP2, 5′-AGCAGCCATAGAGCT
GGCCCTT-3′ (forward) and 5′-AGCAAAACCAGGA
GCCATGTGCC-3′ (reverse); β-actin: 5´-TCATGAAG
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TGTGACGTGGACATC-3´ (forward) and 5´-CAGGA
GGAGCAATGATCTTGATCT-3´ (reverse). Reactions
were performed with an initial cDNA synthesis step
at 50 °C for 5 min, followed by the denaturation
step at 95 °C for 2 min and PCR amplification cycles
(40 cycles at 95 °C for 15 s, 60 °C for 1 min). Rela-
tive expression levels for MRP1 or MRP2 were nor-
malized to the β-actin by the MxPro-Mx3000P
system. The relative expressions of MRP genes were
reported as the target/reference ratio of the treated
samples divided by the target/reference ratio of the
untreated control sample.
Statistical analysis
Results (mean ± SD) were reported in three independent
stages. Statistical analyses were performed by SPSS ver-
sion 16.0 using ANOVA, with the Tukey's post-hoc to
show significant differences between the data and p
values < 0.05 were considered significant.
Results
Effect of crocin on the proliferation rate of A2780 cancer
cell lines
To investigate the effects of crocin on the cell survival of
ovarian cancer cells, A2780 cells were incubated in the
presence or absence of various concentrations of crocin
(0–100 μM) for 4, 24, 48 and 72 h and then subjected to
MTT cytotoxicity assay. Crocin showed inhibitory effects
on the cell growth rate of A2780 cells in a concentration
and time-dependent manner (Fig. 1a). Crocin exhibited a
similar inhibitory pattern with less potency in A2780/RCIS
(Fig. 1b), in which treatment with 60–100 μM and 80–
100 μM of crocin significantly reduced the survival of
A2780 and A2780/RCIS, respectively (P < 0.05 vs. control).
Fig. 1 The effects of crocin on cell viability of A2780 (a) and A2780/RCIS (b) cell lines. The cells were incubated with various concentrations of
crocin at 37 °C for 4, 24, 48 and 72 h. Cell viability was measured by the MTT assay. Each experiment was repeated independently three times in
triplicate tests and data are shown as mean ± SD. *P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001
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Expression of MRP1 and MRP2 in A2780 cell lines
Real-time RT-PCR was used to assess the basic level of
the mRNA expression of MRP1 and MRP2 in cisplatin-
resistant A2780/RCIS cells and sensitive parental A2780
cell line. As shown in Fig. 2a, the MRP1 mRNA level in
the A2780/RCIS cell line was 1.29 times more than its
expression level in A2780 cells. Also, the results showed
that the expression level of MRP2 mRNA in the resistant
cell line A2780/RCIS was about 13 times more than the
MRP2 mRNA level in parental A2780 cells (Fig. 2b).
Effect of crocin on MRP1 and MRP2 gene expression
To evaluate the expression of MRP1 and MRP2 mRNA
after treatment with crocin, the cells were treated with
different concentrations of crocin (0–100 μM) for 4 and
48 h. Expression of MRP transporters was studied using
Real-time RT-PCR. The results showed that crocin sig-
nificantly reduced the expression level of MRP1 (up to
about 50 %) in A2780/RCIS cells at 48 h (Fig. 3a). Simi-
larly, crocin could significantly reduce MRP2 mRNA ex-
pression (up to 60 %) in cisplatin-resistant A2780/RCIS
cells in a time dependent manner in compared with the
control level (Fig. 3b).
Effect of crocin on multi-drug resistance protein activity
In order to evaluate the effects of crocin on MRP trans-
porters activity, sensitivity of tested cell lines to doxo-
rubicin in the presence or absence of crocin were
studied. At first it was necessary to find the IC50 of
doxorubicin on A2780 and A2780/RCIS cells. For this
purpose, cells were treated with different concentrations
of doxorubicin (0–500 nM) for 4, 24, 48, and 72 h.
Doxorubicin significantly reduced the proliferation rate
of A2780 (Fig. 4a) and A2780/RCIS cells (Fig. 4b) in a
concentration and time-dependent manner. These anti-
proliferative effects of doxorubicin were with a higher
intensity in the parental cisplatin-sensitive cell line
A2780 in comparison with the resistant cell line A2780/
RCIS.
To test the combining effects of crocin and doxorubi-
cin on the cell survival of A2780 cell lines, 30 different
combinations (0–100 μM of crocin with 0–500 nM of
doxorubicin) were evaluated using MTT assay. The com-
binatorial effects on cell survival were analyzed after 4,
24, 48, and 72 h incubation. There were no significant
differences in A2780 cell viabilities between all crocin +
doxorubicin concentrations and controls with the same
amount of doxorubicin (data not shown). On the other
hand, different concentrations of crocin could increase
the percentage of doxorubicin cytotoxicity in A2780/
RCIS, almost all in a time and concentration-dependent
manner (Table 1). While crocin could not change the
A2780/RCIS cell sensitivity to doxorubicin in 4 h, there
were significant differences between the IC50 of samples
that were treated with crocin + doxorubicin and IC50 of
controls that were with the same amount of doxorubicin
after 48 h (144 nM vs. 349 nM, P < 0.001) and 72 (162 nM
vs. 326 nm, P < 0.01).
Discussion
Multidrug resistance (MDR) is one of the most import-
ant reasons for the insufficient effectiveness of chemo-
therapy drugs in cancer treatment. A major mechanism
involved in MDR, is the presence of some of the ATP-
binding cassette transporters (ABC) like Multidrug
resistance-associated proteins 1 and 2 (MRP1 and MRP2),
Fig. 2 Basal expressions of MRP1 (a) and MRP2 (b) mRNA in ovarian cancer cell lines were studied by real-time RT-PCR. The MRP mRNA level is
compared with the drug-resistant cell line A2780/RCIS and parental drug-sensitive cell line A2780. Real-time RT-PCR analysis was performed on
total RNA extracted from cells. Values were normalized to the β-actin content of samples and expressed as mean ± SD (n = 3).
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which are expressed on the surface of cells and pumps
chemotherapy drugs out of the cell. In recent years, sci-
entists have tried to find efficient inhibitors of special
ABC transporters to overcome MDR phenomenon [27].
Crocin, a major constitute of saffron [10], has shown
anticancer activities against several cancer cell lines
[19–23], and could be used clinically for the prevention
and treatment of cancer in the near future. In this
study, we evaluated the effects of crocin on the expres-
sion and function of MRP1 and MRP2 in the human ovar-
ian carcinoma cell line A2780 and MRP2-overexpressing
cell line A2780/RCIS.
It has been previously shown that induction of the
MRP2 expression in human cancer cell lines enhances
the resistance to doxorubicin [28], while down regula-
tion of MRP2 enhances cell sensitivity to doxorubicin
[29]. Based on these studies and similar studies for
MRP1, doxorubicin has been introduced as a substrate
of MRP1 and MRP2 transporters [30]. The results of the
present study have shown that the MRP1 and MRP2 ex-
pression level in the cisplatin-resistant A2780/RCIS cell
line was 1.29 and 13 times more than its expression level
in its parental sensitive cell line A2780, respectively. On
the other hand, doxorubicin had anti-proliferative effects
Fig. 3 The effects of crocin on the levels of MRP1 (a) and (b) mRNA in the A2780/RCIS cell line. Cells were treated for 4 and 48 h with crocin
(0–100 μM), and MRP1 and MRP2 mRNA expressions were measured by real-time RT-PCR using total RNA extracted from control and treated
cells. Values were normalized to the β-actin content of the samples. The results were expressed as the target/reference ratio of the treated samples
divided by the target/reference ratio of the untreated control sample and expressed as mean ± SD (n = 3); *, p < 0.05; **, p < 0.01; ***, p < 0.001
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on the A2780 cells with higher intensity when compared
with the A2780/RCIS cell line. These results indicated
that the higher expression of MRP transporters in
A2780/RCIS was accountable for the higher efflux of
doxorubicin that resulted to its lower intracellular con-
centration and lower anti-proliferative activity in this
drug-resistant cell line. Interestingly, crocin has shown a
similar inhibitory pattern on cell growth of tested cell
lines in which its anti-proliferative activity had less po-
tency in A2780/RCIS in compared with the parental sen-
sitive cell line. Totally, these results suggest that crocin
could be a substrate of MRP transporters.
Several studies have investigated the molecular mech-
anism of anticancer activities of crocin against different
human cancer cell lines. In one study, the differentially
expressed gene of the bladder cancer T24 cell line after
treatment with or without crocin has been evaluated
using the cDNA microarray. The results showed that
under crocin treatment, 836 genes were up-regulated or
down-regulated, which were replication factor or were
involved in cell cycle controlling and DNA cell apoptosis
[31]. Similarly, other studies have shown that crocin
could arrest the tumor cell cycle and induce apoptosis
by inhibition of the expression of Bcl-2, survivin, cyclin
D1, and lactate dehydrogenase A (LDHA) or by up-
regulation the expression and activity of Bax and nuclear
factor erythroid 2-related factor 2 (Nrf2), and by inhib-
ition of the telomerase activity [10, 19, 20, 32, 33]. The
investigation of cellular targets of crocin using prote-
omic screening showed that crocin physically binds to a
wide range of cellular proteins such as membrane trans-
porters and enzymes involved in ATP and redox homeo-
stasis [34]. In another study, researchers investigated the
inhibition ability of a selection of carotenoids including
β-carotene, crocin, retinoic acid, canthaxanthin, and
fucoxanthin on the P-glycoprotein (P-gp; MDR1). These
Fig. 4 The effects of doxorubicin on cell viability of A2780 (a) and A2780/RCIS (b) cell lines. The cells were incubated with different concentrations of
doxorubicin (0–500 nM) for 4, 24, 48 and 72 h. Cell viability was measured by the MTT assay. Each experiment was repeated independently three times
in triplicate tests and data are shown as mean ± SD. *P≤ 0.001
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carotenoids decreased P-gp mRNA expression levels; in-
creased accumulation of cytotoxic agents which are P-gp
substrates that cause to enhance their cytotoxicity ef-
fects. Totally, they concluded that carotenoids could be
used as adjuvants which are chemosensitizer in chemo-
therapy [35].
In this study, we aimed to evaluate the effects of cro-
cin on MRP transporter expression and function. For
this purpose the sensitivity of tested cell lines to doxo-
rubicin in the presence or absence of non-toxic concen-
trations of crocin were studied. The MRP activity assay
has been designed in two ways, short time exposure
with crocin to evaluate the direct interaction between
crocin and existing active transporters, and longtime
exposure with crocin to evaluate the indirect effect of
crocin on the transporter activity as a result of its mod-
ifications on the expression level. Interestingly, crocin
could not change the A2780/RCIS cell sensitivity to
doxorubicin in 4 h, while it significantly increased
doxorubicin cytotoxicity after 48 and 72 h in a
concentration-dependent manner in the drug-resistant
A2780/RCIS cell line, but not in parental drug-sensitive
A2780 cells. On the other hand, the real-time PCR re-
sults showed that crocin significantly reduced the
mRNA expression level of MRP1 and MRP2 in A2780/
RCIS cells. Totally, these results indicated that crocin
could suppress drug resistance via down regulation of
MRP gene expression in the human ovarian cancer re-
sistance cell line.
Conclusion
In this study we aimed to investigate the ability of cro-
cin on inhibiting multidrug resistance in human ovarian
cancer cells by interfering with MRP 1 and MRP2
transporters. The results showed that crocin could de-
crease the gene expression of MRP1 and MRP2 and
exert MDR reversal, and enhance the cytotoxicity of
doxorubicin in the human MRP2 overexpressing cell
line A2780/RCIS. This study suggests that the applica-
tion of crocin in combination with chemotherapeutics
in cancer treatment could be an effective method to
improve the efficacy of chemotherapy and moderate the
impact of MDR.
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Table 1 The effects of different concentrations of crocin on the cell survival percentages of A2780/RCIS cell lines under treatment with
doxorubicin (mean ± SEM)
Time (h) Dox (nM) Crocin (μM)
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4 h 16 97.04 ± 2.18 97.39 ± 10.06 95.88 ± 3.49 98.77 ± 3.05
62 92.19 ± 4.94 96.51 ± 2.36 92.57 ± 0.70 95.91 ± 1.34
125 91.52 ± 3.92 95.35 ± 0.91 91.77 ± 4.48 92.74 ± 2.33
250 93.56 ± 2.70 95.13 ± 4.03 83.37 ± 5.05 84.1 ± 2.48
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250 50.13 ± 2.80 33.17 ± 2.96** 34.49 ± 3.05*** 28.09 ± 2.30***
500 36.55 ± 2.82 22.21 ± 1.16 22.66 ± 1.71 9.27 ± 0.93***
Note: The results of the LSD test, which compared the effects of all crocin concentrations on the toxicity of each of the various concentrations of doxorubicin
during 4, 24, 48, and 72 h. *, p < 0.05; **, p < 0.01; ***, p < 0.001
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